{
  "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "docSlug": "9e6f9592721adb102aeba3d640e068ca",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 39,
  "pageCount": 64,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 18,
  "notes": "The slide uses a numbered list format to present clinical milestones and market opportunities.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/39",
  "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "deckJsonHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd.json",
  "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.35,
        "y": 0.0015
      },
      "kind": "list",
      "text": "100% overall response rate in relapsed/refractory AL amyloidosis ($3bn market); No drugs approved in relapsed/refractory AL amyloidosis today (29,712 U.S. patient prevalence); BCMA CAR-Ts are not created equal: NXC-201 designed for high activity in AL Amyloidosis",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ea32698-fcb4-4c07-81f4-33c84dd53d7e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.8,
        "w": 0.3,
        "x": 0.02,
        "y": 0.0015
      },
      "kind": "list",
      "text": "1. First CAR-T, NXC-201, in AL Amyloidosis\n2. Expanding into Additional Autoimmune indications\n3. First “single-day CRS” CAR-T\n4. NXC-201 n=73 patients across 11 peer-reviewed publications\n5. First CAR-T Overcoming Neurotoxicity\n6. IMX-110 - promising results in colorectal cancer with 30 patients dosed",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "734d219e-a5df-4b0f-8eee-18aff97fe41b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.02,
        "y": 0.08
      },
      "kind": "title",
      "text": "NXC-201 FDA Investigational New Drug (IND) Application Already Cleared",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cbac1b15-56a3-46c8-a443-dfd934732528",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "IMMX: Autoimmune CAR-T Company with 73 patients dosed to-date",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3fad1438-1adf-42ba-aa00-6c063f94a32a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "a7c0426a-6ac4-484f-8e68-56c34ba74418",
      "evidence": "Numbered list of key company highlights",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 64,
      "from": 37,
      "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}